ImmunoVaccine Inc. (IMV) Director Buys C$30,080.00 in Stock

ImmunoVaccine Inc. (TSE:IMV) Director Frederic Ors bought 16,000 shares of the stock in a transaction on Tuesday, February 13th. The shares were purchased at an average price of C$1.88 per share, with a total value of C$30,080.00.

ImmunoVaccine Inc. (TSE:IMV) traded up C$0.01 during mid-day trading on Tuesday, reaching C$1.90. The company’s stock had a trading volume of 82,667 shares, compared to its average volume of 143,902. The company has a market cap of $246.44, a PE ratio of -21.00 and a beta of 0.47. ImmunoVaccine Inc. has a 52-week low of C$1.00 and a 52-week high of C$2.55.

COPYRIGHT VIOLATION WARNING: “ImmunoVaccine Inc. (IMV) Director Buys C$30,080.00 in Stock” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/13/immunovaccine-inc-imv-director-buys-c30080-00-in-stock.html.

ImmunoVaccine Company Profile

Immunovaccine Inc, a clinical stage biopharmaceutical company, develops cancer immunotherapies and infectious disease vaccines based on its DepoVax platform. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system.

Receive News & Ratings for ImmunoVaccine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoVaccine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply